| Title |
An early indicator of drug success: Top Journal Selectivity Index
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2013
|
| DOI | 10.2147/dddt.s37324 |
| Pubmed ID | |
| Authors |
Igor Kissin |
| Abstract |
The Top Journal Selectivity Index (TJSI) is a scientometric index reflecting the potential importance of a new drug. It represents the ratio of the number of all types of articles on a particular drug in the top 20 journals relative to the number of articles in all (>5,000) biomedical journals covered by Medline over the 5 years since the drug's introduction. The TJSI can be an indicator of a drug's potential for sustained use: a higher score increases the probability of continuing success. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 5% |
| Australia | 1 | 5% |
| Unknown | 20 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 18% |
| Researcher | 3 | 14% |
| Student > Bachelor | 2 | 9% |
| Lecturer | 2 | 9% |
| Professor > Associate Professor | 2 | 9% |
| Other | 5 | 23% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 18% |
| Medicine and Dentistry | 4 | 18% |
| Computer Science | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Social Sciences | 2 | 9% |
| Other | 3 | 14% |
| Unknown | 4 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2013.
All research outputs
#17,031,938
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#1,034
of 2,283 outputs
Outputs of similar age
#190,394
of 293,412 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 22 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,412 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.